This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Moderna's Revenues See Strong International Momentum in Q1 Earnings
by Zacks Equity Research
MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.
MRKPositive Net Change MRNAPositive Net Change ABUSPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
by Zacks Equity Research
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
AGENPositive Net Change AMRNPositive Net Change ANABPositive Net Change RCKTNegative Net Change
biotechs earnings
BDTX Shares Gain 11% in a Week: Here's What You Should Know
by Zacks Equity Research
Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
AMRNPositive Net Change LQDAPositive Net Change BDTXPositive Net Change INDVPositive Net Change
biotechs
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
by Zacks Equity Research
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
AMRNPositive Net Change ANIPPositive Net Change HRMYPositive Net Change INDVPositive Net Change
biotechs earnings medical
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
by Ahan Chakraborty
Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
by Zacks Equity Research
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
AMRNPositive Net Change TBPHPositive Net Change VTRSPositive Net Change INDVPositive Net Change
biotechs
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
by Zacks Equity Research
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
VRTXPositive Net Change AGENPositive Net Change AMRNPositive Net Change CRSPPositive Net Change
biotechs
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
by Zacks Equity Research
XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.
NBIXPositive Net Change AMRNPositive Net Change XENEPositive Net Change LQDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.
AMRNPositive Net Change LQDAPositive Net Change KODPositive Net Change INDVPositive Net Change
biotechs
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
by Zacks Equity Research
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
SNYNegative Net Change BIIBPositive Net Change DNLIPositive Net Change TAKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals